Glaukos Stock News

Glaukos Corporation (NYSE:GKOS ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Tom Burns – Chairman & Chief Executive Officer Joe Gilliam – President & Chief Operati

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos Corporation (GKOS) said it had begun a Phase 2 clinical trial to test its third generation therapy, iLink, to treat keratoconus, a thinning disorder of the…

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Glaukos Corporation (GKOS) CEO Tom Burns on Q4 2021 Results - Earnings Call Transcript

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced | February 22, 2022

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include: Net sales of $73.2 million in Q4 2021. Glaucoma net sales of $57.1 million and Corneal Health net sales of $16.2 million in Q4 2021. Gross margin of

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock